ALT

Altimmune, Inc. NASDAQ

Healthcare ·Biotechnology ·US · altimmune.com

$3.06

Mkt Cap $270.1M

52w Low $2.56 9.7% of range 52w High $7.73

50d MA $3.46 200d MA $4.03

P/E (TTM) -2.8x

EV/EBITDA -3.3x

P/B 1.1x

Debt/Equity 0.2x

ROE -39.2%

P/FCF -4.7x

RSI (14) —

ATR (14) —

Beta 0.34

50d MA $3.46

200d MA $4.03

Avg Volume 4.1M

About

Altimmune, Inc., a clinical stage biopharmaceutical company, focuses on developing treatments for obesity and liver diseases. The company's lead product candidate, pemvidutide (proposed INN, formerly known as ALT-801), is a GLP-1/glucagon dual receptor agonist that is in Phase 1b trial for the treatment of obesity and non-alcoholic steatohepatitis. It is also developing HepTcell, an immunotherapeu…

Recent Earnings

Date	Time	Est	Rptd	Surp	Base	Gap%	D1%	D2%	D3%	D4%	D5%	Guide ▲★
Mar 5, 2026	AMC	-0.25	-0.27	-8.0%	3.51	+0.9%	+0.9%	+10.5%	+10.0%	+8.3%	+2.6%	—
Nov 6, 2025	AMC	-0.29	-0.21	+27.6%	3.94	-0.5%	+4.3%	+8.1%	+8.6%	+7.4%	+3.0%	—
Aug 12, 2025	AMC	-0.32	-0.27	+15.6%	3.62	+0.6%	+3.3%	+1.7%	+0.3%	-1.7%	+0.0%	—
May 13, 2025	AMC	-0.35	-0.26	+25.7%	5.76	+0.5%	-1.0%	+0.3%	-3.1%	-4.5%	+1.6%	—
Feb 27, 2025	AMC	-0.34	-0.33	+2.9%	6.42	-2.6%	+3.6%	-6.7%	-7.2%	-10.9%	-12.9%	—
Nov 12, 2024	AMC	-0.36	-0.32	+11.1%	9.49	+2.7%	+0.3%	-10.9%	-19.8%	-24.7%	-21.3%	—
Aug 8, 2024	AMC	-0.34	-0.35	-2.9%	6.33	+1.1%	-2.5%	-1.7%	-0.3%	-2.4%	-1.4%	—
May 9, 2024	AMC	-0.36	-0.34	+5.6%	7.72	-0.9%	-6.5%	-4.5%	+1.3%	+14.9%	+15.3%	—
Mar 27, 2024	AMC	-0.35	-0.33	+5.7%	8.89	+1.9%	+14.5%	+15.1%	+5.3%	+4.5%	+0.1%	—
Nov 7, 2023	AMC	-0.40	-0.39	+2.5%	2.70	-0.4%	+0.0%	-9.3%	-7.4%	-9.6%	-10.7%	—
Aug 10, 2023	AMC	-0.44	-0.32	+27.3%	3.04	+0.3%	-1.0%	-2.0%	-7.6%	-10.5%	-11.5%	—
May 11, 2023	AMC	-0.49	-0.40	+18.4%	5.33	+1.1%	-4.5%	-9.0%	-12.8%	-13.7%	-16.5%	—

Recent Analyst Ratings

Date	Firm	Action	Grade	Target	Base	Open	Gap%	D1%	D2%	D3%	D4%	D5%
Apr 24	Goldman Sachs	Upgrade	Sell → Neutral	$2	$2.89	$2.95	+2.1%	-1.4%	-3.1%	-5.2%	-9.0%	-10.0%
Mar 16	HC Wainwright & Co.	Maintains	Buy → Buy	—	$3.50	$3.60	+2.9%	+3.4%	+0.9%	-2.3%	-2.3%	-4.6%
Mar 6	B. Riley Securities	Maintains	Buy → Buy	—	$3.51	$3.54	+0.9%	+0.9%	+10.5%	+10.0%	+8.3%	+2.6%
Nov 7	Citizens	Maintains	Market Outperform → Market Outperform	—	$3.94	$3.92	-0.5%	+4.3%	+8.1%	+8.6%	+7.4%	+3.0%
Oct 20	HC Wainwright & Co.	Maintains	Buy → Buy	—	$3.83	$3.87	+1.0%	+4.4%	+5.5%	+1.8%	+3.4%	+3.1%
Oct 10	HC Wainwright & Co.	Maintains	Buy → Buy	—	$4.00	$4.03	+0.8%	-2.0%	+0.0%	-0.8%	+0.0%	-2.8%
Aug 13	UBS	Maintains	Buy → Buy	—	$3.62	$3.64	+0.6%	+3.3%	+1.7%	+0.3%	-1.7%	+0.0%
Aug 13	B. Riley Securities	Maintains	Buy → Buy	—	$3.62	$3.64	+0.6%	+3.3%	+1.7%	+0.3%	-1.7%	+0.0%
Aug 13	HC Wainwright & Co.	Maintains	Buy → Buy	—	$3.62	$3.64	+0.6%	+3.3%	+1.7%	+0.3%	-1.7%	+0.0%
Jul 10	JMP Securities	Maintains	Market Outperform → Market Outperform	—	$4.74	$4.00	-15.6%	-7.2%	-12.7%	-10.1%	-11.8%	-11.8%
Jun 27	HC Wainwright & Co.	Maintains	Buy → Buy	—	$3.61	$3.64	+0.8%	-3.0%	+7.2%	+17.2%	+35.7%	+31.9%
Apr 3	HC Wainwright & Co.	Maintains	Buy → Buy	—	$4.78	$4.48	-6.3%	-6.7%	-11.3%	-16.7%	-23.2%	-11.5%
Apr 2	Citizens Capital Markets	Maintains	Market Outperform → Market Outperform	—	$4.75	$4.67	-1.7%	+0.6%	-6.1%	-10.7%	-16.2%	-22.7%
Mar 14	Citizens Capital Markets	Maintains	Market Outperform → Market Outperform	—	$5.20	$5.39	+3.7%	+13.8%	+14.8%	+7.9%	+11.7%	+11.2%
Mar 3	HC Wainwright & Co.	Maintains	Buy → Buy	—	$6.65	$6.71	+0.9%	-9.9%	-10.4%	-14.0%	-15.9%	-16.2%
Feb 5	HC Wainwright & Co.	Maintains	Buy → Buy	—	$6.64	$6.70	+0.9%	+5.3%	+4.1%	+0.3%	-0.5%	-5.3%
Jan 23	HC Wainwright & Co.	Maintains	Buy → Buy	—	$6.94	$6.86	-1.2%	+1.7%	+0.6%	+0.9%	-0.1%	+0.1%
Jan 22	HC Wainwright & Co.	Maintains	Buy → Buy	—	$6.83	$6.81	-0.3%	+1.6%	+3.4%	+2.2%	+2.5%	+1.5%
Nov 14	HC Wainwright & Co.	Maintains	Buy → Buy	—	$9.52	$9.55	+0.3%	-11.1%	-20.1%	-24.9%	-21.5%	-15.4%
Aug 12	B. Riley Securities	Maintains	Buy → Buy	—	$6.17	$6.17	+0.0%	+0.8%	+2.3%	+0.2%	+1.1%	+5.2%
Jun 25	B. Riley Securities	Maintains	Buy → Buy	—	$7.14	$7.11	-0.4%	+3.8%	-12.3%	-10.5%	-6.9%	+0.8%
Jun 21	Piper Sandler	Maintains	Overweight → Overweight	—	$5.94	$6.00	+1.0%	+7.9%	+20.2%	+24.7%	+5.4%	+7.6%
May 14	HC Wainwright & Co.	Maintains	Buy → Buy	—	$7.37	$7.53	+2.2%	+6.1%	+20.4%	+20.8%	+8.7%	+9.1%
May 10	JMP Securities	Maintains	Market Outperform → Market Outperform	—	$7.72	$7.65	-0.9%	-6.5%	-4.5%	+1.3%	+14.9%	+15.3%
Apr 29	Guggenheim	Downgrade	Buy → Neutral	—	$7.26	$6.86	-5.5%	-11.8%	-9.8%	-2.6%	-1.0%	+0.6%
Apr 1	HC Wainwright & Co.	Maintains	Buy → Buy	—	$10.18	$10.25	+0.7%	+0.5%	-8.1%	-8.7%	-12.6%	-10.7%
Mar 28	B. Riley Securities	Maintains	Buy → Buy	—	$8.89	$9.06	+1.9%	+14.5%	+15.1%	+5.3%	+4.5%	+0.1%
Feb 13	B. Riley Securities	Maintains	Buy → Buy	—	$10.40	$9.88	-5.0%	-18.7%	-13.4%	-13.9%	-15.8%	-19.2%
Dec 1	HC Wainwright & Co.	Maintains	Buy → Buy	—	$3.16	$5.74	+81.6%	+13.0%	+46.5%	+63.6%	+117.7%	+108.2%
Nov 9	B. Riley Securities	Maintains	Buy → Buy	—	$2.70	$2.71	+0.4%	-9.3%	-7.4%	-9.6%	-10.7%	-9.6%
Aug 14	HC Wainwright & Co.	Maintains	Buy → Buy	—	$3.01	$3.01	+0.0%	-1.0%	-6.6%	-9.6%	-10.6%	-12.0%
Aug 11	B. Riley Securities	Maintains	Buy → Buy	—	$3.04	$3.05	+0.3%	-1.0%	-2.0%	-7.6%	-10.5%	-11.5%
Jul 12	JMP Securities	Maintains	Market Outperform → Market Outperform	—	$3.38	$3.43	+1.5%	-1.8%	+0.3%	-3.0%	-5.9%	-6.8%
May 15	HC Wainwright & Co.	Maintains	Buy → Buy	—	$5.09	$5.15	+1.2%	-4.7%	-8.6%	-9.6%	-12.6%	-11.8%
Mar 31	JMP Securities	Maintains	Market Outperform → Outperform	—	$4.22	$4.21	-0.2%	+0.0%	+4.7%	-2.4%	-8.3%	-5.0%
Mar 22	JMP Securities	Maintains	Market Outperform → Outperform	—	$4.95	$4.99	+0.8%	-15.2%	-15.4%	-12.7%	-2.6%	-10.7%
Mar 22	Goldman Sachs	Downgrade	Buy → Neutral	—	$4.95	$4.99	+0.8%	-15.2%	-15.4%	-12.7%	-2.6%	-10.7%
Mar 9	HC Wainwright & Co.	Maintains	Buy → Buy	—	$11.05	$11.08	+0.3%	+2.9%	-6.2%	-2.4%	+0.4%	-1.1%
Feb 6	JMP Securities	Maintains	Market Outperform → Outperform	—	$15.16	$15.10	-0.4%	+0.5%	+0.1%	-8.6%	-7.5%	-11.4%
Jan 20	HC Wainwright & Co.	Maintains	Buy → Buy	—	$14.96	$14.96	+0.0%	-4.1%	-2.6%	-5.3%	-6.2%	-7.0%
Jan 18	Evercore ISI	Maintains	Outperform → Outperform	—	$14.96	$15.26	+2.0%	+0.1%	+0.0%	-4.1%	-2.6%	-5.3%
Dec 1	Goldman Sachs	Maintains	Buy → Buy	—	$9.95	$10.80	+8.5%	+8.4%	+13.4%	+11.2%	+3.5%	+2.8%
Nov 11	JMP Securities	Maintains	Market Outperform → Market Outperform	—	$10.58	$10.35	-2.2%	+1.0%	+0.1%	+3.2%	-9.8%	-16.9%
Sep 16	Guggenheim	Maintains	Buy → Buy	—	$14.39	$14.22	-1.2%	-5.0%	-10.9%	-12.4%	-11.8%	-7.2%
Aug 31	Jefferies	Maintains	Buy → Buy	—	$18.94	$19.20	+1.4%	+16.6%	+15.3%	+18.3%	+11.5%	+6.9%
Aug 17	HC Wainwright & Co.	Maintains	Buy → Buy	—	$17.66	$17.87	+1.2%	-2.7%	+2.5%	-2.8%	+0.2%	+4.4%
Aug 12	B. Riley Securities	Maintains	Buy → Buy	—	$13.77	$13.80	+0.2%	+26.1%	+27.4%	+28.2%	+24.8%	+31.4%
May 18	Piper Sandler	Maintains	Overweight → Overweight	—	$5.29	$5.13	-3.0%	-8.5%	-8.9%	-5.1%	-8.3%	-10.8%
Jun 30	JMP Securities	Maintains	Market Outperform → Market Outperform	—	$15.90	$10.71	-32.6%	-38.1%	-36.9%	-41.3%	-44.2%	-47.0%
Jun 30	B. Riley Securities	Maintains	Buy → Buy	—	$15.90	$10.71	-32.6%	-38.1%	-36.9%	-41.3%	-44.2%	-47.0%

Recent Filings

8-K

Altimmune, Inc. -- 8-K Filing

Altimmune's capital raise will fund its Phase 3 trial for pemvidutide in MASH and pre-commercial activities, providing runway to advance its lead metabolic disease program.

Apr 24

8-K · 5.03 ! Medium

Unknown — 8-K 5.03: Amendment to Articles / Bylaws

Altimmune increased authorized shares, enabling potential dilution for future fundraising or acquisitions, which could pressure existing shareholders' ownership percentages and earnings per share.

Apr 16

8-K

Altimmune, Inc. -- 8-K Filing

Altimmune reports full-year 2025 results and reaffirms its late-stage development focus on pemvidutide for metabolic dysfunction-associated fatty liver disease, positioning the candidate as a differentiated treatment option for serious liver conditions.

Mar 5

8-K · 8.01 !! High

Altimmune, Inc. -- 8-K 8.01: Material Event / Announcement

Altimmune scheduled its 2026 Annual Meeting for April 16, 2026, with a March 13 record date, allowing shareholders to vote on corporate matters.

Feb 3

Data updated apr 24, 2026 5:32pm · Source: massive.com